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DIFFERENTIAL RESPONSE TO RITUXIMAB IN ANTI-ACHR AND ANTI-MUSK
POSITIVE MYASTHENIA GRAVIS PATIENTS: A SINGLE-CENTER
RETROSPECTIVE STUDY
Tess Litchman1, Bhaskar Roy1 Aditya Kumar1, Aditi Sharma1, Valentine Njike2, Richard J.
Nowak1
1

Yale School of Medicine, Department of Neurology, New Haven, Connecticut, USA, 2Griffin HospitalDerby, Yale University Prevention Research Center, Derby, CT, USA.

Response to immunomodulatory therapies in myasthenia gravis (MG) can be variable. A
subset of MG patients remains refractory to conventional agents. B-cell targeted therapy
with rituximab has demonstrated a durable response in treating refractory myasthenia
gravis (MG). This study compares the response to rituximab between patients with
acetylcholine receptor autoantibody positive (AChR+) and muscle-specific kinase
autoantibody positive (MuSK+) MG.

This retrospective study included 33 patients with either AChR+ or MuSK+ MG who
were treated with rituximab from 05/31/2003 to 05/31/2017. Pretreatment and posttreatment immunotherapy regimens, clinical symptoms, and examination findings were
evaluated.

Median MGFA Class of II at baseline improved to an asymptomatic median classification
at 12-months and last follow-up (p-values <0.001) post-rituximab. Improvement in
MGFA class was not significantly different between the groups. Twenty-one patients
achieved clinical remission (12/17 AChR+, 9/16 MuSK+) with time to remission of
441.4 ± 336.6 days for AChR+ versus 230 ± 180.8 days for MuSK+ patients (p-value
0.049). The mean prednisone dosage requirement decreased significantly in both groups

3
post-rituximab (p-value <0.01). AChR+ patients required more hospitalizations for
exacerbation post-rituximab (p-value 0.046).

In conclusion, rituximab therapy is observed to have both a clinical benefit and durable
response in the majority of AChR+ and MuSK+ MG patients with refractory disease,
supporting the role of B cell depletion in the management of MG. While there was no
significant difference between these groups in terms of clinical improvement, symptomfree state, and prednisone burden, MuSK+ MG patients may experience greater benefits,
including earlier time to remission, fewer exacerbations and hospitalizations posttreatment.
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INTRODUCTION
Background
Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction
characterized by muscular weakness and fatigue. Autoantibodies bind to the
acetylcholine receptors or functionally related proteins in the postsynaptic membrane of
the neuromuscular junction, causing decreased uptake of acetylcholine and consequent
skeletal muscle weakness1-4. The estimated prevalence of MG is approximately 1-2 per
100,000 with an estimated annual incidence of 7-20 cases per 100,0005.

Muscular weakness is the defining clinical characteristic of MG. Muscles typically
involved include the extraocular muscles, leading to ptosis and diplopia, as well as the
bulbar muscles, leading to difficulties with speech and swallowing. While oculobulbar
involvement is more common, manifestations can generalize to include weakness of the
proximal muscles of the extremities and trunk. Generalized muscular involvement is
typically symmetric, while ocular involvement is often asymmetric1. Fifteen percent of
MG patients have disease restricted only to the ocular muscles, whereas 85% have
generalized disease6. Weakness is worsened by repetitive muscle use and varies in
severity throughout the day, often worst at the end of the day. Respiratory muscle
weakness and consequent respiratory failure can occur with severe disease. However,
with adequate treatment, most patients can maintain stable disease characterized only by
mild muscle weakness.
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MG Subtypes
MG is classified into subgroups defined by clinical manifestations, age at onset, thymus
pathology, and serology. Up to 80% of MG patients have autoantibodies to the
acetylcholine receptor (AChR) and 5-10% have autoantibodies against muscle-specific
kinase (MuSK); 20-30% of the patients who do not have autoantibodies against AChR or
MuSK have autoantibodies to lipoprotein-receptor-related protein 4 (LRP4)1,7-10. The
remaining 5-10% of MG patients are described as seronegative. Up to 40% of patients
who lack autoantibodies to AChR have autoantibodies to muscle-specific kinase
(MuSK)10, making the AChR and MuSK seropositive subtypes the two most common
subgroups of MG. The pathogenesis in AChR+ MG is understood to be primarily due to
the action of IgG1 autoantibodies which cause a loss of AChR through internalization
and localized complement-mediated postsynaptic tissue damage11-13. MuSK+ MG is
characterized by the action of IgG4 antibodies which cause the inhibition of the agrinLRP4-MuSK pathway by masking binding sites on MuSK, leading to reduced AChR
clustering on the postsynaptic membrane14-16. A complete description of the molecular
pathophysiology of myasthenia gravis is beyond the scope of this thesis.

The AChR+ and MuSK+ MG subtypes have been found to have different clinical
manifestations. The age of presentation for AChR+ MG follows a bimodal pattern, with
peaks at 30 years and 70 years of age. MuSK+ MG patients typically present later with a
peak onset after 50 years of age17. MuSK+ MG has been found to be more common in
the Mediterranean and southern Europe than in northern Europe and is more common in
the northern regions of Asia than in the southern regions18-20. These regional differences
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are thought to be due to genetic predisposition rather than environmental factors.
Thymoma is typically only seen in AChR+ MG, and AChR+ MG patients respond well
to thymectomy even if no thymoma is found. MuSK+ MG patients usually have no
response to thymectomy, as would be expected due to the less prominent role of the
thymus in the pathophysiology of MuSK+ MG; the lesser role of the thymus in MuSK+
MG is demonstrated histologically by the lack of thymic hyperplasia and other thymic
changes normally seen in AChR+ MG patients21-23. Patients with MuSK+ MG have been
found to have more severe clinical manifestations including more facial and bulbar
muscular involvement, as opposed to the proximal limb weakness seen in AChR+ MG
patients21. Craniobulbar muscle involvement can ultimately be seen in up to 82%-100%
of patients with MuSK+ MG24. Bulbar-onset MuSK+ MG is usually associated with a
more rapidly progressive course 24. Patients with MuSK+ MG tend to have more severe
disease manifestations, demonstrated in studies with higher mean QMG scores and
MGFA subclasses7,25,26. Myasthenic crises have been observed to occur 2 to 3 more times
in MuSK+ MG patients than in AChR+ MG patients26,27. Classifying myasthenia into
subgroups can help guide individualized treatment.

Current treatment options
MG was originally thought to be a disorder of hysteria; at that time, the prescribed
treatment was bed rest and avoidance of too much excitement28. Fortunately, much more
is known about MG today. With the first described case most likely dating back to 1664,
as detailed by settlers in Virginia of the “excessive fatigue” and drooping eyelids of
Native American Chief Opechancanough29, MG is one of the oldest identified
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neuromuscular disorders, and consequentially its pathophysiology is very well
understood. Nonetheless, clinical trials have been challenging to conduct due to the
disease’s rarity and fluctuating nature. This has led to significant variation in the
management of MG.

While there is general agreement in the neurology community on the use of many
treatments for MG, there is no accepted universal standard of care due to the variability in
presentation, subtype, and treatment response. In the setting of MG being a rare disease,
there have been few randomized controlled trials to date, mainly limited by patient
recruitment. The studies that have been conducted30-32 often have limited generalizability
due to low statistical power, strong patient preferences to take or not take steroids, the
long latency of action for many of the agents used in treatment of MG, and the
heterogeneous presentation of the disease itself33-36. The ultimate goal of treatment for
MG is to render the patient asymptomatic or to lessen the patient’s symptom burden as
much as possible while minimizing side effects from medications. Accordingly, treatment
response is graded with clinical scoring systems such as the Quantitative Myasthenia
Gravis (QMG) and Myasthenia Gravis Foundation of America (MGFA) classification
scores. Autoantibody titers following treatment have not been found to correlate with
treatment response in AChR+ MG patients37. In this study, AChR autoantibody levels fell
in 92% of patients who improved, but also in 63% of patients who did not improve. Thus,
following autoantibody levels is not a reliable way to determine treatment response; it is
necessary to rely on clinical indicators.
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Initial treatment typically includes symptom management with acetylcholinesterase
inhibitors, usually pyridostigmine. The mechanism behind these agents is simple:
acetylcholinesterase inhibitors delay the degradation of acetylcholine (ACh) in the
neuromuscular junction, prolonging the effect of ACh and thereby leading to
improvement in strength38. Acetycholinesterase inhibitors only provide symptomatic
treatment and are usually not sufficient for disease control for patients with generalized
MG. However, some patients can be maintained on pyridostigmine alone. Major side
effects include GI upset, but more rarely cholinergic crisis. All groups of MG tend to
show some response to acetylcholinesterase inhibitors, but patients with MuSK+ MG
have been reported to show a less robust response to pyridostigmine than patients with
AChR+ MG20,39. One study noted a nonresponsiveness rate of 71% in MuSK+ MG
patients versus 18% of MG patients negative for MuSK+ antibodies, similar to findings
in other studies39,40.

For a patient who remains symptomatic on pyridostigmine therapy, the next step in
escalation of care is to add immunosuppression. Corticosteroids are often the first-line
agent1,30,41. Treatment effects are dose-dependent, as are side effects. Treatment is
typically initiated at a high dose then de-escalated, such as with a transition to an
alternate-day regimen. Remission (30%) or marked improvement (45%) occurs in over
75% of patients treated with this regimen42. However, many patients with generalized
MG require the addition of a nonsteroidal immunosuppressive agent for disease
maintenance, including agents such as azathioprine, cyclosporine, mycophenolate
mofetil, or tacrolimus43-45. Expert consensus and some randomized controlled trials have
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supported azathioprine as the preferred first-line immunosuppressive agent in MG after
steroids41,46-48. Azathioprine can be used in conjunction with prednisone in patients with
inadequate response to prednisone or alone in patients with adverse side effects from the
steroids49. If this regimen fails, patients can be transitioned to mycophenolate mofetil
(MMF) or another agent. The delayed onset of action of azathioprine and its adverse
effects have spurred interest in alternative agents such as the immunomodulatory drugs.
Once patients achieve their treatment goals with their immunosuppressive regimen, the
corticosteroid dose can be gradually tapered. Many patients require long-term
maintenance with a low-dose corticosteroid. MuSK+ MG patients have been reported to
respond less well to immunosuppressive therapy than AChR+ MG patients, experiencing
by a lower remission rate and more difficulty in tapering steroids24,39,50.

Thymectomy, for MG patients with or without thymoma, can also be used as an
adjunctive therapy. Thymectomy has been shown to be beneficial in the treatment of
generalized AChR+ MG and is recommended for these patients. A recent large
randomized controlled trial that compared thymectomy plus prednisone to prednisone
alone found improvement in clinical outcomes in patients with non-thymomatous MG,
characterized by improvement in clinical status, fewer hospitalizations, and lesser
requirements for prednisone and azathioprine therapy51. The two-year follow-up of this
study similarly found long-lasting benefits of thymectomy in patients with generalized
non-thymomatous MG when compared with prednisone alone52. Thymectomy is not
recommended for patients with MuSK+, LRP4, or ocular forms of MG because no
benefit has been established. A recent randomized, retrospective multicenter blinded
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review compared thymectomy outcomes for patients with AChR+ vs MuSK+ MG and
found that thymectomy was not associated with additional clinical improvement in
MuSK+ MG patients53.

Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) are used as short-term
“rescue” therapies in patients with MG experiencing life-threatening acute disease
exacerbations characterized by respiratory insufficiency or dysphagia in which rapid
response to treatment is necessary, as maintenance therapy for patients not adequately
managed by corticosteroids, or as preoperative treatment before thymectomy41,54. A
myasthenic crisis is defined as a need for intubation caused by muscle weakness related
to the disease. IVIg and PLEX may be given for a severe MG exacerbation and are
always indicated for myasthenic crisis. Multiple randomized controlled trials have
demonstrated that IVIg and PLEX are likely equally efficacious in the treatment of severe
generalized MG55,56. In an emergent situation, expert consensus suggests that PLEX is the
preferred agent due to its faster onset of action41,57. Patient factors must be taken into
consideration when choosing one agent over the other. For example, PLEX cannot be
used in septic patients and catheter placement can be complex due to need for access to
large veins. Several contraindications also exist for IVIg, including hypercoagulable
states, renal failure, and hypersensitivity to immunoglobulin41,58. IVIg was associated
with less severe side effects and found to be cheaper and more convenient in a registrybased observational study58
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Treatment-refractory MG
Despite the wide arsenal of therapies available, a small subset of MG patients remains
refractory to conventional therapy. Treatment-refractory MG is characterized by
persistent and disabling weakness despite treatment, disease relapses while tapering
treatment, or treatment-related adverse effects. International consensus guidelines have
established criteria for refractory MG as “PIS [Post-Intervention Status] is unchanged or
worse after corticosteroids and at least 2 other immunosuppressive agents, used in
adequate doses for an adequate duration, with persistent symptoms or side effects that
limit functioning, as defined by patient and physician”41. Clinical studies have typically
used the following criteria in their definitions of treatment-refractory MG59-63, as detailed
in a 2018 review written by Mantegazza and Antozzi63:
1) Insufficient response to conventional therapy, defined by maximal safe doses of
steroids and at least one immunosuppressive drug of adequate dose and duration
2) Inability to reduce immunosuppressive therapy without clinical relapse or a
need for ongoing rescue therapy such as intravenous immunoglobulin G (IVIg) or
plasma exchange (PE)
3) Severe or intolerable adverse effects from immunosuppressive therapy
4) Comorbid conditions that restrict the use of immunosuppressive therapy
5) Frequent myasthenic crises even while receiving therapy

The exact prevalence of treatment-refractory myasthenia gravis is not currently known,
but has been observed in approximately 10-15% of patients with generalized MG in
several studies conducted at tertiary referral clinics60,61,64. Patients with refractory MG
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have been observed to more likely be female, anti-MuSK+, thymomatous, and have an
early age of onset61,64. Currently, the main treatments in use for refractory generalized
MG include rituximab and eculizumab. No consensus exists on the ideal treatment
algorithm for treatment-refractory generalized MG.

The humanized monoclonal antibody eculizumab, a complement inhibitor, has recently
been approved for use in treatment-refractory generalized AChR+ MG, making it the first
immunomodulatory treatment approved for treatment of MG in the United States65.
Eculizumab binds to C5 complement protein and inhibits the activation of terminal
complement, thus protecting the neuromuscular junction from damage from the
complement cascade66. A randomized, double-blind placebo-controlled phase II study
reported that refractory patients had improved clinical outcomes as demonstrated by
improvement in QMG score post eculizumab treatment67. This was followed by the
randomized, placebo-controlled phase III REGAIN trial, which, although did not
demonstrate a statistically significant benefit with its prespecified primary endpoint of
improvement in activities of daily living (MG-ADL), did support the efficacy of
eculizumab with prespecified and posthoc sensitivity analyses and other secondary
outcomes for use in treatment-refractory generalized AChR+ MG68. It was later approved
by the US Food and Drug Administration (FDA) for adults with generalized AChR+ MG
in 2017. Eculizumab would not be expected to work in MuSK+ MG patients because
IgG4 autoantibodies are not involved in complement-mediated immunopathology.
Notably, given the novelty of the medication, annual costs of eculizumab for one patient
are approximately $500,000, with some variation per dose and country, making it one of
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the most expensive therapies in the world69. Rituximab, an alternative
immunomodulating agent, shows similarly promising results and is less expensive for the
patient, as well as provides an option for treatment-refractory patients with generalized
MuSK+ MG.

B-cell targeted therapy with rituximab has shown durable response in treating refractory
MG. Rituximab is a genetically engineered chimeric mouse-human monoclonal antibody
directed against CD20, a transmembrane protein found on the surface of Blymphocytes54,70,71. CD20 is involved in the initiation of the cell cycle and in the
activation, differentiation and growth of B-lymphocytes72,73. The Fab domain of
rituximab binds to CD20 cells and recruits immune effector cells for B-cell lysis54. CD20
B-cell levels are decreased for over 6 months following rituximab therapy. Rituximab has
been approved for use in non-Hodgkin B-cell lymphoma74 and many autoimmune
disorders, such as rheumatoid arthritis75, type 1 diabetes76, immune thrombocytopenia77,
among others. To note, rituximab has not been approved for use in MG and continues to
be administered as an off-label treatment. The increasing use of rituximab in MG still
lacks supportive evidence from randomized controlled trials. BeatMG, a recently
concluded multicenter double-blind placebo-controlled phase II clinical trial in AChR+
MG, did not provide conclusive evidence in support of rituximab therapy for MG78. The
BeatMG study demonstrated a favorable safety profile for rituximab, however, met the
primary futility outcome at 52-weeks, suggesting that there would be a low probability of
achieving the prespecified steroid-sparing effect difference in a similar mildly

16
symptomatic cohort on concomitant immunotherapy78,79. To note, this study was not
limited to refractory disease or powered to assess efficacy.

The benefits of rituximab in MG have however been reported in multiple case reports and
series59,62,80-87. Treatment of MG with rituximab has been shown to result in sustained
clinical improvement, as well as allowing for tapering and discontinuing of other
immunotherapies62,88. A retrospective meta-analysis conducted in 2015 of MG patients
treated with rituximab found an overall response rate of 83.9% in the patient cohort89. A
large retrospective nationwide study recently conducted in Austria demonstrated that over
two-thirds of their patient cohort improved to an MGFA-PIS of MM or better after
rituximab therapy90. Rituximab is an appealing option because it provides a steroidsparing therapeutic option with potentially long-lasting effects. The varying responses of
the AChR+ and MuSK+ MG subtypes will be discussed in the next section.

Differences in response to rituximab between MG subtypes
MG patients are typically initially treated similarly regardless of their serotype84. As
mentioned above, several studies have suggested that MuSK+ patients have a more
severe form of the disease and may be more resistant to established treatments than
AChR+ MG patients26,91-94.

Several small studies have suggested that MuSK+ MG patients respond well to rituximab
and tend to respond better and have more prolonged improved clinical outcomes
compared to AChR+ MG patients25,50,80,84,94-98. A multicenter blinded, prospective review

17
of MuSK+ MG demonstrated better clinical outcomes with rituximab as compared with
other treatment regimens, including improved clinical status and ability to taper
prednisone99. A small single-center study that examined 11 AChR+ MG and 6 MuSK+
MG patients refractory to conventional agents treated with rituximab found demonstrable
improvement in clinical status post rituximab treatment in all patients, with longer-lasting
effects in the MuSK+ MG patients, i.e. reduced concurrent immunosuppressant
requirements and no need for reinfusions as compared to the AChR+ MG patients80. A
2017 meta-analysis of 169 MG patients treated with rituximab demonstrated clinical
status improvement in both AChR+ and MuSK+ groups with fewer relapses in MuSK+
MG post-rituximab compared to AChR+ MG54. This same review found that a
significantly greater proportion of MuSK+ MG patients as compared with AChR+ MG
patients achieved post-rituximab PIS-m of MM or better or CSR or PR, as well as a
greater decrease in their QMG scores54. This study also found that antibody titers in
MuSK+ MG may be a more useful monitoring tool than in AChR+ MG. The
aforementioned Austrian study published in 2015 reported that more MuSK+ MG
patients achieved remission (71.4% vs 35.9%, p=0.022) compared to AChR+ MG
patients after treatment with rituximab90.

Current guidelines state that rituximab should be reserved as an escalation therapy for
AChR+ MG after failing conventional therapy41,90. Understanding how MuSK+ MG
patients respond to rituximab may impact future recommendations and promote the use
of rituximab to a first-line agent, or at least for use earlier in the treatment algorithm.
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Additional long-term follow-up studies are needed to investigate and further characterize
the differential response to rituximab treatments between AChR+ and MuSK+ patients.

In this study, we report our experience with rituximab in 33 patients with generalized MG
seen at the Yale Myasthenia Gravis Clinic, 17 with AChR+ MG and 16 with MuSK+
MG, who had an average follow-up of approximately 5 years. We analyzed the difference
in treatment response between the AChR+ and MuSK+ MG patients.

STATEMENT OF PURPOSE
Targeted therapies, specifically B-cell directed therapeutics, have shown growing
promise as effective tools in the management of autoimmune disorders. While
small studies and large meta-analyses have been published suggesting a differential
response between anti-AChR+ and anti-MuSK+ patients, there is need for more large
single-center comparisons between the groups to corroborate this data. We report our
experience with the long-term effects of rituximab treatment in thirty-three MG patients
followed at the Yale Myasthenia Gravis Clinic. To our knowledge, this retrospective
report represents the largest, single-center MG cohort in the U.S. focused on studying
possible key differences between these antibody groups. We believe that this work will
fill a critical gap in our current knowledge as well as be of significant interest to the
neurology community.
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Hypothesis:
We hypothesize that there will be a difference in response to rituximab between
subgroups and that there will be clinical differences between the MuSK+ and AChR+
subtypes of MG patients that will be reflected in their differential responses to rituximab
treatment.

Specific Aims of Study:
Aim 1: Time to Clinical Response: We will determine the difference in time from
initiation of rituximab treatment to observed clinical benefit between the two groups.

Aim 2: Rate of Steroid Reduction: We will determine how quickly each group was able
to taper prednisone after initiation of rituximab.

While steroids are considered the mainstay therapy in the treatment of MG, they are
associated with many unwanted side effects if used long-term. The current standard of
care approach is to transition patients to a steroid-sparing agent. We will look at the
ability of patients to reduce their steroid dose after the initiation of rituximab. The
differences in rate of this reduction will be determined between the AChR+ and MuSK+
MG groups to shed additional insight on differences in responsiveness to rituximab
therapy.

Aim 3: Rescue Therapy Rates: We will determine how frequently each group required
rescue therapy (IVIG or plasmapheresis).
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Aim 4: We will quantify how many disease exacerbations and hospitalizations each
group experienced.

METHODS
Patients
This retrospective study included patients with generalized MG treated with rituximab
therapy and followed for a minimum of 12 months after completion of the initial set of
rituximab treatment cycles (Table 1). We identified 33 patients followed in the Yale
Myasthenia Gravis Clinic, New Haven, Connecticut from May 31, 2003 to May 31, 2017.
This study was approved by the institutional review board of Yale University as part of
an observational study examining the treatment and disease course of MG. All patients
provided written informed consent.

Rituximab was administered in cases when the immunotherapy dosage could not be
lowered without clinical relapse, adequate clinical control could not be achieved, and/or
patients experienced severe adverse effects due to the current immunosuppressive
therapy.

Pretreatment and post-treatment immunotherapy regimens, clinical symptoms, and
examination findings were evaluated. These included prednisone (which is the standard
first-line agent), plasma exchange (PLEX), azathioprine, mycophenolate mofetil, and
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intravenous immunoglobulin (IVIg). The number of administered rituximab treatment
cycles, time since last treatment cycle, time to relapse, time to remission, and the type of
post-relapse treatments were also reviewed. The Myasthenia Gravis Foundation of
America (MGFA) clinical classification criteria100 and post-intervention status (PIS) were
used to assign clinical state 12 months after completion of the initial set of rituximab
cycles and at last visit. We defined “improved clinical status” when Complete Stable
Remission (CSR), Minimal Manifestations (MM), and/or Improved (I) PIS change was
achieved. Remission was defined as when the patient achieved "asymptomatic" status
based on the MGFA classification and had not relapsed for 12 months. Exacerbation was
defined as when a patient had clinically deteriorated based on a worsened MGFA class.

Rescue therapy was defined as the need for the addition of an immunotherapy (IVIg or
PLEX) during a disease exacerbation. This was quantified via chart review by noting for
each disease exacerbation which treatments were used. Maintenance therapy was defined
as regularly scheduled immunotherapy treatments (IVIg or PLEX). These were quantified
via chart review of regularly scheduled treatments for the patient. Concomitant use of
other immunosuppressive agents and their daily dosing was also reviewed.
Rituximab
Patients were treated with an initial 2- to 4- cycle regimen, except for two patients who
only received 1 cycle. Because no established infusion protocol for rituximab use in MG
currently exists, the MG clinic used a standard protocol adopted from the non-Hodgkin
lymphoma regimen of 4 weekly infusions of 375 mg/m2. One cycle is defined as 1
infusion per week for 4 consecutive weeks. The interval between cycles was 6 months.
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The number of rituximab treatment cycles or intervals between cycles was not dictated by
B-cell counts but rather based on clinical improvement and patient tolerance of tapering
or withdrawal of other immunotherapies (i.e. corticosteroids).

Statistical Analysis
Statistical analysis was performed using R version 1.4.3. Descriptive statistics are
represented as mean ± standard deviation if not specified otherwise. Wilcoxon-signed
rank tests for paired analysis, and Mann-Whitney U-test for unpaired analysis were used
for non-parametric data. Paired or unpaired t-test was used for parametric data as
applicable. χ2 test or Fisher’s exact test were used for nominal data as applicable. KaplanMeier survival curves were generated with log-rank test to study the duration of response
to rituximab. Significance was defined as p-value of < 0.05.

RESULTS
Thirty-three patients were identified (17 AChR+, 16 MuSK+; mean age 35.9 ± 15.6
years; 24 women and 9 men) with a mean follow-up of 1861 ± 953.4 days. Twentyseven patients (87.9%) were receiving prednisone prior to initiation of rituximab therapy.
The mean number of induction rituximab cycles received was 3.1 ± 1.3.

The AChR+ and MuSK+ groups were well matched overall. There were no significant
differences between the AChR+ and MuSK+ groups in terms of age at onset of disease,
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gender, length of follow-up, or number of rituximab cycles received. Key differences
noted were that the number of patients receiving either IVIg or PLEX maintenance
therapy prior to rituximab was higher in the MuSK+ group (4/17 in AChR+ vs. 11/16 in
MuSK+, p-value 0.02) and the number of patientswho underwent thymectomy was
higher in the AChR+ group (15/17 in AChR+ vs. 5/16 in MuSK+, p-value <0.01) (Table
1).

The median baseline MGFA Clinical Class was II for the entire group, which improved
to asymptomatic (0) both at 12-months and last follow-up (p-values <0.01) after
rituximab treatment (Table 1, Figure 1). The median MFGA Clinical Class for AChR+
patients improved from a baseline of II to asymptomatic (0) at 12-months (p-value <0.01)
and at last visit (p-value <0.01) after rituximab treatment. Similarly, MuSK+ patients
improved from a median baseline class of II to asymptomatic (0) at 12-months (p-value
<0.01) and at last follow-up visit (p-value <0.01) (Figure 1).
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Table 1: Demographics and baseline characteristics.

Demographics
Age at onset, mean (SD)
Female, n (%)
Worst MGFA classification,
median (range)
Thymoma, n (%)
Duration of disease in days before
rituximab, mean (SD)

All patients
(n=33)

AChR (n=17)

MuSK
(n=16)

pvalue

35.9 (15.6)
24 (72%)
III (II-V)

33 (25)
10 (58%)
III (II-V)

34.8 (14.9)
14 (87%)
III (II-V)

0.70
0.12
0.19

7 (21%)
1579.4 ± 2423.8

7 (46%)
1169.2 ± 762.6

0 (0%)
2025.9 ±
3391.1

0.06
0.33

Length of follow-up in days, mean
1861.5 (953.4)
1196.1 (743.9)
1718.6
(SD)
(1143.1)
Current and previous treatment
Patients on prednisone when
29 (87%)
16 (94%)
13 (81%)
starting rituximab, n (%)
Prednisone dose in mg/day, mean
39.1 (23.9)
46.8 (20.8)
30.9 (24.9)
(SD)
Patients on maintenance IVIg
and/or PLEX, n (%)
15 (46%)
4 (24%)
11(69%)
Use of oral steroid sparing
agents^, n (%)
17 (51%)
9 (53%)
9 (56%)
Patients with previous rescue
therapy with IVIg and/or PLEX, n
(%)
29 (87.9%)
16 (94%)
13 (81.3%)
Previous thymectomy, n (%)
20 (61%)
15 (88%)
5 (31%)
Time from thymectomy to 1st cycle 940.6 (1096.9)
730.6 (589.3)
1675.5
of rituximab, mean (SD)
(2094.7)
Disease exacerbation prerituximab
Number of exacerbations, mean
1.7 (2.9)
2.6 (2.7)
0.8 (0.9)
(SD)
Rituximab therapy
Number of rituximab cycles, mean
3.1 (1.3)
3.1 (0.9)
3.1 (1.7)
(SD)
^Azathioprine (6 AChR+, 4 MuSK+); mycophenolate mofetil (3 AChR+, 4 MuSK+);
cyclosporine (1 MuSK). IVIg, intravenous immunoglobulin; PLEX, plasma exchange.

0.41

0.26
0.06

0.02
0.86

>0.9
<0.01
0.44

0.06

>0.9
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The median baseline MGFA Clinical Class was II for the entire group, which improved
to asymptomatic (0) both at 12-months and last follow-up (p-values <0.01) after
rituximab treatment (Table 1, Figure 1). The median MFGA Clinical Class for AChR+
patients improved from a baseline of II to asymptomatic (0) at 12-months (p-value <0.01)
and at last visit (p-value <0.01) after rituximab treatment. Similarly, MuSK+ patients
improved from a median baseline class of II to asymptomatic (0) at 12-months (p-value
<0.01) and at last follow-up visit (p-value <0.01) (Figure 1).

Figure 1: MGFA classification of AChR+ and MuSK+ patients at baseline, and at 12
months and last visit post-rituximab

Figure 1: MGFA clinical class at baseline, 12-months, and at last visit for AChR+ and MuSK+
patients. (A) The median MGFA clinical class for AChR+ patients improved from a baseline of II
to asymptomatic (0) at 12-months (p-value <0.01) and at last follow-up visit (p-value <0.01) postrituximab. (B) Similarly, MuSK+ patients improved from a median baseline MGFA clinical class
of II to asymptomatic (0) at 12-months (p-value <0.01) and at last follow-up visit (p-value <0.01).
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MM or better PIS was attained at 12-months in 10 (58.8%) AChR+ patients and 11
(68.8%) MuSK+ patients, respectively (p-value 0.72). At last follow-up MM or better
PIS was attained in 11 (64.7%) and 12 (75%) of AChR+ and MuSK+ patient
respectively. Twenty-one patients achieved clinical remission (12 AChR+, 9 MuSK+)
with time to remission of 441.4 ± 336.6 days for AChR+ versus 230 ± 180.8 days for
MuSK+ patients (p-value 0.049) (Figure 2, Table 2). Overall, the MuSK+ group
required a shorter period of time to achieve remission, as defined by MGFA class of
asymptomatic without any relapse for 12 months.

Percent in Remission

Figure 2: Time to remission between AChR+ and MuSK+ following rituximab
treatment.

Figure 2: Time to remission between AChR+ (n=9) and MuSK+ (n=12) patients post-rituximab (days since
start of first rituximab infusion). Comparison data shown is only for those that achieved clinical remission.
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The mean prednisone dose requirement decreased in both groups following rituximab
treatment (AChR+: baseline 46.8 ± 20.8 mg/day, 12-months 11.8 ± 15.3 mg/day, last
follow-up 17.9 ± 15.6; MuSK+: baseline 30.9 ± 24.9 mg/day, 12-months 9.5 ± 8.7
mg/day, last follow-up 2.8 ± 3.8 mg/day). While this was significant within groups (pvalue < 0.01), there was no significant difference between the two groups (baseline pvalue 0.057, 12-months p-value 1, last follow-up p-value 0.75) (Table 1, Table 2, Table
3). There was also no significant difference between the groups in terms of ability to
taper off prednisone completely or to reduce the daily dose of prednisone ≤ 10 mg (pvalues 0.69 and 0.49 respectively). The length of time required to taper off prednisone
completely or ≤ 10 mg/day post-rituximab also did not defer significantly between the
groups (p-values 0.4 and 0.08 respectively) (Table 2).

The most commonly used steroid sparing agents in our cohort were azathioprine (AZA)
and mycophenolate mofetil (MMF). Only one patient in the MuSK+ group was on
cyclosporine only before rituximab infusion. Overall use of steroid sparing agents was
significantly reduced following rituximab treatment [18 patients at baseline, 8 patients at
12-months (p-value 0.02), and 5 patients at last follow-up (p-value 0.002)]; however, this
did not reach statistical significance when AChR+ and MuSK+ groups were considered
separately. There was no significant difference between the groups in terms of successful
reduction of concomitant use of steroid sparing agents (Table 2, Table 3).
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Table 2: Outcome measures post-rituximab therapy.

Clinical outcome:
MM or better at 12 months, n (%)
MM or better at last visit, n (%)
Patients with clinical remission^, n (%)
Days to remission, mean (SD)
Patients with relapse, n (%)
Days to relapse, mean (SD)
Steroid-sparing effect:
Prednisone dose at 12-months in mg/day, mean
(SD)
Prednisone dose at last visit in mg/day, mean
(SD)
Able to taper prednisone to ≤10 mg/day, n (%)
Time to ≤10 mg/day in days, mean (SD)
Able to taper prednisone completely, n (%)
Time to taper prednisone completely in days,
mean (SD)
Disease exacerbation:
Number of exacerbations, mean (SD)
Number of patients hospitalized for
exacerbations, n (%)
Steroid sparing agents:
Use of oral steroid sparing agents, n (%)
Maintenance therapy:
Number of patients requiring maintenance
therapy with IVIg and/or PLEX, n (%)
Total number of IVIg and/or PLEX treatment
cycles, Mean (SD)
Rescue therapy:
Number of patients requiring rescue therapy with
IVIg and/or PLEX, n (%)
Total number of IVIg and/or PLEX treatment
cycles, Mean (SD)

AChR (n=17)

MuSK
(n=16)

p-value

10 (58.8%)
11(65%)
12 (70.6%)
441.4 (336.6)
10 (58.8%)
824.1 ± 479.3

11 (68.8%)
12 (75%)
9 (56.3%)
230 (180.8)
6 (37.5%)
1529 ±
1338.4

0.72
0.71
0.39
0.049
0.22
0.09

11.8 (15.3)

9.5 (8.7)

1

17.9 (15.63)

2.8 (3.8)

0.75

14 (82%)
361.9 (232.8)
12 (70%)
811.4 ± 395.6

13 (81%)
219.1 (152.0)
9 (56%)
712.4 ± 395.6

0.49
0.08
0.69
0.4

1.7 (1.2)

1.4 (1.1)

0.42

5 (29%)

0 (0%)

0.045

3 (18%)

2 (12.5%)

>0.9

6 (35.3%)

6 (43.8%)

1

9.8 (31.8)

9.1 (19.8)

0.77

7 (41.2%)

3 (18.8%)

0.26

0.7 (1.1)

0.5 (1.1)

0.27

^ clinical remission was defined as when the patient achieved "asymptomatic" status based on the MGFA
classification and had not relapsed for 12 months.
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Table 3: Comparison of treatment burden between the AChR+ and MuSK+ group
Prerituximab
Prednisone use
Prednisone dose (pre-rituximab
and 1 year)
Prednisone dose (last visit)
Steroid sparing agent use
Azathioprine
Mycophenolate mofetil
Cyclosporine
Maintenance IVIg and PLEX
Number of patients on maintenance IVIg and PLEX
treatments
Total number of maintenance
IVIg and PLEX treatments, n
(SD)
Rescue IVIg and PLEX
Number of patients on rescue
IVIg and PLEX treatments
Total number of rescue IVIg
and PLEX treatments, n (SD)

46.8
(20.8)

AChR
Postrituximab

pvalue

11.6
(14.7)
17.9 ±
15.6

<0.01

6
3
0

3
0
0

0.43
0.22
NA

4

6

22.3
(61.3)

MuSK
PrePostrituximab rituximab
30.9
(24.9)

pvalue

5.9 (8.0)

<0.01

2.3 ± 3.8

<0.01

4
4
1

2
0
0

0.65
0.10
NA

0.71

11

6

0.16

9.8
(31.9)

0.29

21.7
(27.2)

9.1
(19.8)

0.21

16

7

<0.01

13

3

<0.01

2.1 (1.2)

0.7(1.1)

<0.01

2.1 (2)

0.5 (1.1)

0.02

<0.01
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Figure 3: Time to relapse between AChR+ and MuSK+ following rituximab treatment.

Figure 3. (A) Time to relapse between all AChR+ and MuSK+ patients post-rituximab. (B) Time
to relapse between AChR+ and MuSK+ patients who received ≥ 3 cycles of rituximab. All
patients are included in this analysis. Time reflects days since start of first rituximab infusion.

Sixteen (48.5%) patients relapsed after rituximab therapy (Table 2). The relapse rate was
58.8% and 37.5% for AChR+ and MuSK+ patients respectively (p-value 0.22). There
was no significant difference in time to relapse between AChR+ and MuSK+ patients (pvalue 0.09) (Figure 3B). However, when the cohort was restricted to patients who
received ≥ 3 rituximab cycles, MuSK+ patients relapsed later than AChR+ patients (pvalue 0.03) (Figure 3C). AChR+ patients had more MG-related hospitalizations as
compared to MuSK+ patients during the entire follow-up period (p-value 0.045) (Table
2).

We examined the effect of rituximab treatment on the total burden of IVIg and PLEX
required as maintenance therapy. There was no statistically significant reduction
compared to pre-rituximab in either the AChR+ or MuSK+ group (p-value 0.29 and 0.21
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respectively). Similarly, the number of patients requiring maintenance IVIg or PLEX was
not significantly different in either group post-rituximab therapy compared to prerituximab (p-values 0.71 and 0.16 respectively). There was also no difference between
the AChR+ and MuSK+ groups in terms of total number of maintenance therapy
requirement post-rituximab infusion (p-value 0.77).

Fewer patients required IVIg or PLEX as rescue therapy following rituximab in both
groups (p-values <0.01). Similarly, the number of rescue therapies required either with
IVIg or PLEX reduced significantly in both AChR+ and MuSK+ patients post-rituximab
therapy (p-value <0.01 and 0.02 respectively). However, there was no significant
difference between groups in terms of number of patients requiring rescue therapy or the
total number of rescue therapy events required post-rituximab (p-values 0.26 and 0.27
respectively) (Table 2, Table 3).

Twenty patients had undergone thymectomy (60.6%), of whom 7 (21.1%) had a
thymoma (Table 1). All patients with a thymoma were AChR+. While the thymoma
subgroup received more rituximab cycles (3.6 ± 0.9 vs. 2.5 ± 0.8, p-value 0.03), there
were no significant differences found between the thymoma vs non-thymoma groups in
terms of aforementioned clinical outcomes.

All patients in the study tolerated rituximab treatment without severe adverse side effects
identified per chart review.
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DISCUSSION
Targeted immunotherapies demonstrate great potential for a subset of MG patients who
are refractory to or have adverse effects from conventional immunosuppressive
treatments. Depletion of B cells with rituximab, with its established precedence in other
autoimmune disorders such as rheumatoid arthritis101-103, pemphigus104,105, autoimmune
hemolytic anemia106,107, has availed itself as an appealing next-line option.

In this retrospective analysis of 33 patients with refractory AChR+ or MuSK+ MG and
extended follow-up, a long-lasting clinical benefit was again observed following
rituximab therapy88. These results support the findings from previous studies
demonstrating the benefit of rituximab in managing refractory MG62,80,108-110.
Additionally, our findings add valuable insights regarding whether B-cell depletion
therapy should be utilized as an induction regimen. The study also provides information
on the expected rate of relapse after achieving remission following completion of an
induction regimen. The overall relapse rate in our entire cohort was 48.5%, occurring
approximately 2.7 years after treatment (992 ± 783.9 days). While the relapse rate was
similar to those previously reported80,111, the duration of disease stability was longer in
our cohort. Prednisone burden was also successfully reduced in both groups. While
concomitant use of steroid-sparing agents was reduced among the whole cohort,
statistical significance was not achieved when groups were considered separately, which
may be related to small sample size with between-group analysis. There were some
trends suggesting that the MuSK+ group may experience greater benefit from rituximab,
specifically a faster time to remission and a longer time to relapse, which is further
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supported by more frequent MG-related hospitalizations and need for rescue therapy in
the AChR+ group.

Despite its interesting observations, this report is limited by the retrospective nature of
our study, varied baseline immunotherapy regimens and number of rituximab treatment
cycles. Unfortunately, it does not adequately establish the presence of
differential response to rituximab between AChR+ and MuSK+ patients or whether
antibody status is a predictor of response or durability.

In our healthcare system, rituximab use is mostly restricted to the outpatient setting.
While our study included patients with refractory generalized disease, in the attempt to
stabilize patients prior to start of infusions, the majority of the patients were categorized
as mild-moderate in severity (based on MGFA class) at the time of rituximab initiation.
This may have resulted in a scale floor effect masking any possible difference between
groups. Due to the MGFA classification only being a gross measure of disease severity,
true burden of disease differences could not be assessed as other outcomes were not
available for analysis, such as MG Activities of Daily Living (MG-ADL) or Quantitative
MG (QMG) scores.

While there is strong evidence that AChR+ and MuSK+ MG are distinct disease entities
with unique autoantibody-mediated immunopathologic mechanisms10,11, dramatic clinical
differences were not noted with anti-CD20 therapy. B-cell depletion appears to benefit
both groups of patients. As a clearer picture emerges regarding pathogenic B-cell
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populations and whether these populations return upon B-cell recovery, the application of
targeted therapy can be better tailored to each patient.

Why is there a difference between AChR+ and MuSK+ patients in their response to
rituximab?
Multiple recent studies have corroborated earlier data suggesting that MuSK+ MG
patients may have a more robust response to rituximab therapy than AChR+ MG
patients80,89,112. As mentioned above, a multicenter blinded, prospective review of
MuSK+ MG conducted in 2017 demonstrated better clinical outcomes with rituximab as
compared with other treatment regimens, including improved clinical status and ability to
taper prednisone99. The same year, a meta-analysis of 169 MG patients treated with
rituximab demonstrated clinical status improvement in both AChR+ and MuSK+ groups,
with fewer relapses in MuSK+ MG post-rituximab compared to AChR+ MG54. These
larger studies added to the field of growing evidence that MuSK+ MG patients may
respond better to rituximab than AChR+ MG patients. However, this differential
treatment effect is still not fully explained.

There are several hypotheses regarding why there may be differences in response to
rituximab treatment between MuSK+ and AChR+ MG patients. Various theories
regarding disease pathogenesis will be discussed. First, the differential response to
rituximab between MuSK+ and AChR+ MG is thought to be related to the role of longlived plasma cells in the pathogenesis of the two subtypes. A study conducted in 2017
identified the emergence of autoantibody-producing plasmablasts after B-cell depletion in
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patients with MuSK+ MG113. Because remission is achieved in a few months despite
subsequent repopulation of CD20+ cells, the authors of this study suggest that
autoimmunity in MuSK+ MG is driven by short-lived, autoantibody-secreting
plasmablasts. This is opposed to AChR+ MG, in which long-lived CD20- plasma cells
may contribute to autoantibody production. Rituximab only eliminates CD20+ cells and
thus does not affect the long-lived CD20- plasma cells in AChR+ MG. This is
corroborated by the results of an earlier study published in 2012 which demonstrated that
the MuSK+ MG patients had no decline in their anti-tetanus toxoid (ATT) IgG levels
(produced by long-lived plasma cells) after rituximab treatment, despite a concomitant
decrease in IgM levels (primarily produced by plasmablasts)80,114. Another hypothesis
pertains to the difference in IgG subtype: AChR+ MG is mainly IgG1 and IgG3mediated, while MuSK+ MG is driven by IgG4 autoantibodies13,14. While it is not
completely understood why a difference in IgG subtype would affect rituximab response,
this same 2012 study noted that 3 of their MuSK+ MG patients underwent a switch in
subtype from IgG4 to IgG1 after rituximab treatment, suggesting that rituximab may have
acted more on the IgG4 autoantibodies80. The authors of this study hypothesized that
IgG4 antibodies may be produced by short-lived plasma cells. Rituximab has indeed been
noted to be highly effective against IgG4 autoantibodies in pemphigus vulgaris as well as
in other IgG4-associated systemic diseases115; one study noted drastic reductions in IgG4
levels in 15 out of 18 patients who experienced complete remission following rituximab
therapy116. These differences in pathogenesis may explain why the response to rituximab
in AChR+ MG is typically more delayed and the autoantibody titer decline less
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significant than in MuSK+ MG, as rituximab is primarily acting on the CD20+ cells more
prominently involved in the pathogenesis of MuSK+ MG80,88.

Third, differences in cytokine production between AChR+ and MuSK+ MG have been
described; investigating these differences in Th1 and Th2 responses may lead to deeper
understanding of the differential responses to rituximab therapy. One study investigated
the Th2-related pathway in MuSK+ and AChR+ MG by applying ex vivo non-specific Tcell stimulation to peripheral blood mononuclear cells (PBMC) in order to see differential
responses of T-cell derived cytokines117. A difference was noted between the two
subgroups, with increased secretion of Th1- and Th17-related cytokines in the MuSK+
MG patients, including IFN- γ, IL17, and IL21. Another main finding of this study was
the down-regulating effect of immunosuppressive therapy on Th1 cytokines (IFN- γ,
IL12) and up-regulating effect on Th2 cytokines (IL10, IL6) in AChR+ MG patients, but
not MuSK+ MG patients117. The authors of this study interpreted these differential
cytokine production patterns under treatment as potentially corroborating previously
reported observations that MuSK+ MG patients are more resistant to immunosuppressive
therapy and have better response to rituximab than AChR+ MG patients. While this
research is still in its early stages, identifying differences in T-cell pathophysiology
between MG subgroups would be useful because rituximab is postulated to affect both Bcell and T-cell function118. Rituximab is thought to affect T-cell function 1) directly: by
depleting the small portion of T-cells which express CD20 on their surface119 and 2)
indirectly: by impacting B-T cell cooperation via B-cell depletion118. Responsiveness to
rituximab has been associated with expansion of the T-regulatory population after
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treatment. In one case series, a treatment-responsive MuSK+ MG patient experienced a
long-lasting increase in circulating Treg levels, while the nonresponsive AChR+ MG
patient was noted to have inconsistent fluctuations in Treg cells120. An important followup study will be to perform T-cell repertoire analysis to examine whether rituximab
causes modification to the antigen-specific T-cell repertoire and phenotype 118,121. Gaining
a better understanding of the differences in the pathogenesis of AChR+ and MuSK+ MG
and their response to rituximab can pave the way for more personalized treatment plans.

Additional discrete differences are continuing to be identified in the pathogenesis of the
two major subtypes of MG. A study published in 2013 identified lower levels of IL-10
producing B-cells in MG patients compared to healthy controls, which correlate with
more severe disease122. The subset of B-cells that produces IL-10 has been functionally
defined as “regulatory” in mice and humans due to their ability to produce IL-10, which
has an important role in controlling immune responses and preventing autoimmunity123.
Other autoimmune disorders, including rheumatoid arthritis, Graves’ disease, and
systemic lupus erythematosus have been associated with lower levels of IL-10 producing
B cells124-126. In this study from 2013, the patients who responded well to rituximab
therapy demonstrated a rapid repopulation of B10 cells, while patients who did not
respond well to rituximab had a delayed B10 cell repopulation. Although a statistically
significant difference was not found, a trend of baseline higher frequencies of B10 cells
were seen in patients with AChR+ MG as opposed to MuSK+ MG. Patients with MuSK+
MG also appeared to have a faster repopulation of their B10 cells than AChR+ MG
patients, although this also did not reach statistical significance (p=0.072). While the
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significance of these findings is still not completely understood, these results suggest
fundamental differences in the pathophysiology of AChR+ and MuSK+ MG.

Additionally, a recent investigation identified distinct defects in B-cell tolerance
checkpoints in MG, with differing abnormalities unique to the AChR+ and MuSK+
subtypes127. This study performed deep sequencing of the B-cell receptor repertoire and
found that AChR+ MG and MuSK+ MG subjects displayed distinct gene segment usage
biases in both VH and VL sequences within the naïve and memory compartments, with
abnormalities unique to each subtype. However, an earlier study performed by the same
group demonstrated that both the AChR+ and MuSK+ subtypes of MG have defects in
their central and peripheral B-cell tolerance checkpoints128. While the significance of
these findings is not fully understood yet, the results of these studies again suggest
fundamental differences in the pathophysiology of AChR+ and MuSK+ MG, which
could begin to explain the different disease phenotypes and response to therapy.

Overall these findings suggest various mechanisms behind differences in treatment
response to rituximab between MG subtypes. This remains an active field of research
with much still to be learned.

Future Directions
While rituximab and eculizumab have both shown durable and long-lasting results in
patients with treatment-refractory MG, treatment does not stop there. Given the rapidly
progressing pace of the field of biologics, there continue to be many new exciting
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developments in the area of MG therapy. Further, more research is underway to better
understand the pathophysiology of MG and to explain its varied clinical manifestations.

Despite the results from the BeatMG Study, a phase 2 trial of only AChR+ patients, the
scientific rationale for B-cell depletion in MG is established based on the totality of
published data and experience with CD20-targeted therapy. Further insights from
BeatMG Study subgroup analyses and an ongoing placebo-controlled trial of rituximab in
new onset generalized MG will aid in better elucidating where B-cell depletion therapy
might best fit the overall treatment paradigm129. Further, we must further consider
whether anti-CD19 as opposed to anti-CD20 may be more effective or durable. The
primary objective of B-cell depletion is the elimination of autoantibody producing cells.
In the case of anti-CD20 therapy, this goal is partially achieved by preventing the
formation of new plasma cells from their precursors. As CD20 is generally not expressed
on the majority of autoantibody-producing cells, specifically plasma cells and
plasmablasts, this is one potential disadvantage of an anti-CD20 treatment approach,
especially if these cells are indeed those driving autoantibody production. CD19 is a
transmembrane glycoprotein expressed on early pro-B cells, late pro-B cells, memory Bcells, memory B cells, plasmablasts, and plasma cells130-132 (Figure 5).

40
Figure 5: B cell maturation

Figure 5: Graphical representation of B cell maturation. Green triangles denote populations
targeted by rituximab.

Therefore, because anti-CD19 therapy depletes both plasmablasts and plasma cells due to
the expression of CD19 on these cells, these agents may potentially be more effective at
eliminating production of pathogenic autoantibodies than anti-CD20 agents. There are
several anti-CD19 therapies currently being investigated in clinical settings for B-cell
mediated hematologic malignancies, including blinatumomab, AFM11, MDX-1342,
MOR208, SAR3419, and SGN-CD19A, as well as several agents for autoimmune disease
including XmAb5871 and MEDI-551 (inebilizumab)133. Inebilizumab has been applied to
the experimental autoimmune encephalomyelitis (EAE) animal model of multiple
sclerosis with promising results demonstrate a reduced infiltration of leukocytes into the
spinal cord and a reduction in the number of autoreactive CD138 plasma cells in the
spleen and bone marrow134. Additionally, a recent double-blind randomized placebocontrolled phase 2/3 trial demonstrated the efficacy of inebilizumab in the treatment of
neuromyelitis optica spectrum disorder (NMO)135. The randomized controlled phase of
this study was actually stopped early before complete enrollment, because of a clear
demonstration of efficacy in reducing the risk of an NMOSD attack. To date, anti-CD19
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therapy has not been studied in the treatment of MG. This assumption regarding potential
benefit of anti-CD19 therapy over anti-CD20 needs to be tested in a clinical setting, and
whether this translates into additional or differential clinical benefit between AChR+ and
MuSK+ MG beyond that seen with anti-CD20 therapeutics remains to be seen.

In addition to therapies that directly target cells positive for CD20 and CD19, there has
now been the development of therapies that attempt to prevent the maturation of these
cells. Belimumab, a monoclonal antibody specific against B-cell activating factor
(BAFF), is one such therapy136. BAFF is a survival factor expressed by T cells and
dendritic cells that is necessary for cell proliferation and B-cell maturation137. Studies
have shown that BAFF levels are elevated in patients with AChR+ and MuSK+ MG138.
Belimumab has been approved for use and clinical trials have demonstrated its efficacy in
the treatment of SLE139-141. However, a placebo-controlled multicenter double-blind
study studying the use of belimumab versus placebo in patients with generalized MG
who remained symptomatic despite standard of care therapy did not find any clinical
benefit in terms of reduction in QMG scores136. While not yet shown to be beneficial in
MG, the use of anti-BAFF therapies in the treatment of MG deserves further research.

The role of combination therapy in treating MG is also an important question that
deserves investigation. While combination biologic therapy has not yet been studied on a
large scale in patients with MG, there have been several studies that suggest its efficacy
in patients with SLE. Two randomized controlled studies are currently underway
examining combination therapy with rituximab and belimumab in patients with SLE: a
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phase 3 BLISS-BELIEVE trial comparing combination therapy with belimumab alone142
and a phase 2 BEAT-LUPUS143 clinical trial assessing the safety of combination therapy.
A case series published in 2018 identified 3 patients with active SLE who experienced
clinical remission, ability to taper immunosuppressive therapies, and a reduction of
BAFF levels after combination therapy with rituximab and belimumab144. The same year,
the results of a phase 2A, open-label, single-arm proof-of-concept study were
published145. In this study, 16 SLE patients were treated with a combination of rituximab
and belimumab. The results were promising: 10 patients achieved a low lupus disease
activity state and 14 patients were able to taper concomitant immunosuppressive
medications. This study also specifically examined levels of neutrophil extracellular traps
(NETs), which play an important role in autoimmunity by delivering autoantigens to the
host immune system and for the development of anti-nuclear antibody (ANA), as well as
BAFF levels. BAFF levels have been observed to surge after rituximab treatment, which
has been theorized to stimulate repopulation of autoreactive B-cells. The findings
included that post rituximab and belimumab sequential therapy, patients experienced a
reduction of circulating ANAs and excessive NET formation, a restoration of
complement C3 and C4 levels to normal, a reduction in BAFF levels, and a complete but
transient B-cell depletion with early repopulation of memory B cells and circulating
plasma cells. These promising results in the field of SLE identify a new area of research
in MG waiting to be pursued.
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Non B-cell Therapies
Perhaps with more immediate clinical implications, a study conducted in 2016
demonstrated promising results regarding the use of autologous hematopoietic stem cell
transplantation (HSCT) for treatment of severe MG146. This study observed 7 MG
patients undergoing autologous HSCT (for MG, 1 for follicular lymphoma with
coincident MG) and found that all patients achieved durable MGFA status of complete
stable remission. This study indicates that further research looking into HSCT for
treatment of MG is necessary.

Most recently, a phase II randomized, double-blind, placebo-controlled multicenter study
investigating the safety and efficacy of efgartigimod, an anti-neonatal Fc receptor IgG1
Fc fragment in patients with generalized AChR+ MG, demonstrated that all patients who
received the treatment showed a rapid decrease in total IgG and anti-AChR levels.
Further, a rapid and long-lasting disease improvement was observed in 75% of treated
patients147. FcRn is a protein within the cell that functions to protect the immunoglobulin
molecule from lysosomal degradation by combining with IgG and returning it unharmed
to the cell’s surface148,149. An FcRn inhibitor is an antibody that binds to the native FcRN
and blocks binding to IgG, which leads to degradation of IgG in the lysosome. This study
offers an alternative approach to treating MG via an FcRN-targeted pathway to reduce
pathogenic autoantibodies. Above all else, these new developments reaffirm that the field
of immunomodulatory therapy for autoimmune disorders is constantly evolving.
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The field of monoclonal antibody-based therapies is an exciting and rapidly progressing
one. New targets are constantly being identified for the treatment of MG patients. For
example, research has now spread into interleukin receptor blockade and proteasome
inhibition. Tocilizumab, a monoclonal antibody against IL6, has recently been identified
as a promising therapeutic option in a case study of two patients refractory to
rituximab150. Bortezomib, a proteasome inhibitor, was observed to be effective in a case
study of one patient with MG refractory to rituximab151. Opportunities for more precisely
targeted therapies will arise as more immunopathologic targets are identified, likely
overtaking rituximab in the future.

CONCLUSIONS
Rituximab therapy is a reasonable option for both AChR+ and MuSK+ generalized MG
patients, especially for those with difficult to control disease. While MuSK+ MG patients
may experience greater benefits, a significant differential response between groups was
not observed in our retrospective study. B-cell targeted therapy continues to be a rational
strategy in the MG treatment paradigm. Further investigations are warranted to explore
how B-cell depletion therapy is best applied, especially with the advent of other targeted
treatment options, to achieve improved outcomes which are both meaningful and
sustained in our patients.
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